JP2024524461A5 - - Google Patents
Info
- Publication number
- JP2024524461A5 JP2024524461A5 JP2023580922A JP2023580922A JP2024524461A5 JP 2024524461 A5 JP2024524461 A5 JP 2024524461A5 JP 2023580922 A JP2023580922 A JP 2023580922A JP 2023580922 A JP2023580922 A JP 2023580922A JP 2024524461 A5 JP2024524461 A5 JP 2024524461A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163217716P | 2021-07-01 | 2021-07-01 | |
| US63/217,716 | 2021-07-01 | ||
| PCT/US2022/035995 WO2023278860A1 (en) | 2021-07-01 | 2022-07-01 | Combination treatments in patients with advanced and/or metastatic trop-2 overexpressed cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024524461A JP2024524461A (ja) | 2024-07-05 |
| JPWO2023278860A5 JPWO2023278860A5 (https=) | 2025-07-09 |
| JP2024524461A5 true JP2024524461A5 (https=) | 2025-07-09 |
Family
ID=84692161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580922A Pending JP2024524461A (ja) | 2021-07-01 | 2022-07-01 | 進行性および／または転移性ｔｒｏｐ－２過剰発現ガンを有する治療困難患者における併用治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240139196A1 (https=) |
| EP (1) | EP4362948A4 (https=) |
| JP (1) | JP2024524461A (https=) |
| KR (1) | KR20240029045A (https=) |
| CN (1) | CN118215481A (https=) |
| AU (1) | AU2022301309A1 (https=) |
| CA (1) | CA3223467A1 (https=) |
| IL (1) | IL309489A (https=) |
| TW (1) | TW202317131A (https=) |
| WO (1) | WO2023278860A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL303038B2 (en) | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| TWI842274B (zh) * | 2022-12-15 | 2024-05-11 | 中化合成生技股份有限公司 | 曲拉西利之製備方法及曲拉西利之前驅體 |
| CN120624660A (zh) * | 2024-08-06 | 2025-09-12 | 中山大学附属第三医院 | Fn1抑制剂在制备诊断、预防和治疗结直肠癌骨髓转移的产品中的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202112061RA (en) * | 2019-05-15 | 2021-11-29 | Ayala Pharmaceuticals Inc | Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer |
| EP3986410A4 (en) * | 2019-06-18 | 2023-06-28 | G1 Therapeutics, Inc. | Patient selection for enhancement of anti-tumor immunity in cancer patients |
-
2022
- 2022-07-01 CN CN202280057773.6A patent/CN118215481A/zh active Pending
- 2022-07-01 EP EP22834324.0A patent/EP4362948A4/en active Pending
- 2022-07-01 TW TW111124849A patent/TW202317131A/zh unknown
- 2022-07-01 AU AU2022301309A patent/AU2022301309A1/en active Pending
- 2022-07-01 CA CA3223467A patent/CA3223467A1/en active Pending
- 2022-07-01 IL IL309489A patent/IL309489A/en unknown
- 2022-07-01 WO PCT/US2022/035995 patent/WO2023278860A1/en not_active Ceased
- 2022-07-01 KR KR1020247003327A patent/KR20240029045A/ko active Pending
- 2022-07-01 JP JP2023580922A patent/JP2024524461A/ja active Pending
-
2023
- 2023-12-22 US US18/394,512 patent/US20240139196A1/en active Pending